AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year. Anaptys’ program, known as rosnilimab, hit its primary endpoint across all three ...
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.
Anaptys’ program, known as rosnilimab, hit its primary endpoint across all three ...
